Recombinant human activated protein C ameliorates oleic acid-induced lung injury in awake sheep
Open Access
- 20 November 2008
- journal article
- Published by Springer Nature in Critical Care
- Vol. 12 (6) , R146
Abstract
Introduction: Acute lung injury (ALI) may arise both after sepsis and non-septic inflammatory conditions and is often associated with the release of fatty acids, including oleic acid (OA). Infusion of OA has been used extensively to mimic ALI. Recent research has revealed that intravenously administered recombinant human activated protein C (rhAPC) is able to counteract ALI. Our aim was to find out whether rhAPC dampens OA-induced ALI in sheep. Methods: Twenty-two yearling sheep underwent instrumentation. After 2 days of recovery, animals were randomly assigned to one of three groups: (a) an OA+rhAPC group (n = 8) receiving OA 0.06 mL/kg infused over the course of 30 minutes in parallel with an intravenous infusion of rhAPC 24 mg/kg per hour over the course of 2 hours, (b) an OA group (n = 8) receiving OA as above, or (c) a sham-operated group (n = 6). After 2 hours, sheep were sacrificed. Hemodynamics was assessed by catheters in the pulmonary artery and the aorta, and extravascular lung water index (EVLWI) was determined with the single transpulmonary thermodilution technique. Gas exchange was evaluated at baseline and at cessation of the experiment. Data were analyzed by analysis of variance; a P value of less than 0.05 was regarded as statistically significant. Results: OA induced profound hypoxemia, increased right atrial and pulmonary artery pressures and EVLWI markedly, and decreased cardiac index. rhAPC counteracted the OA-induced changes in EVLWI and arterial oxygenation and reduced the OA-induced increments in right atrial and pulmonary artery pressures. Conclusions: In ovine OA-induced lung injury, rhAPC dampens the increase in pulmonary artery pressure and counteracts the development of lung edema and the derangement of arterial oxygenation.Keywords
This publication has 50 references indexed in Scilit:
- Randomized Clinical Trial of Activated Protein C for the Treatment of Acute Lung InjuryAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Recombinant human activated protein C attenuates endotoxin-induced lung injury in awake sheepCritical Care, 2008
- Beneficial effects of recombinant human activated protein C in a ewe model of septic shock*Critical Care Medicine, 2007
- Recombinant Activated Protein C Induces Dose-Dependent Changes in Inflammatory Mediators, Tissue Damage, and Apoptosis in in Vivo Rat Model of SepsisSurgical Infections, 2007
- Influence of drotrecogin alpha (activated) infusion on the variation of Bax/Bcl-2 and Bax/Bcl-xl ratios in circulating mononuclear cells: A cohort study in septic shock patientsCritical Care Medicine, 2007
- Recombinant human activated protein C upregulates cyclooxygenase-2 expression in endothelial cells via binding to endothelial cell protein C receptor and activation of protease-activated receptor-1Thrombosis and Haemostasis, 2005
- Involvement of thromboxane A2 (TXA2) in the early stages of oleic acid-induced lung injury and the preventive effect of ozagrel, a TXA2 synthase inhibitor, in guinea-pigsJournal of Pharmacy and Pharmacology, 2004
- Expression and function of the endothelial protein C receptor in human neutrophilsBlood, 2003
- Ventilation with Lower Tidal Volumes as Compared with Traditional Tidal Volumes for Acute Lung Injury and the Acute Respiratory Distress SyndromeNew England Journal of Medicine, 2000
- Plasma fatty acid changes and increased lipid peroxidation in patients with adult respiratory distress syndromeCritical Care Medicine, 1996